Sangamo Therapeutics (NASDAQ:SGMO) Given “Buy” Rating at HC Wainwright

Sangamo Therapeutics (NASDAQ:SGMO)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a report released on Thursday,Benzinga reports. They presently have a $10.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s target price would indicate a potential upside of 387.80% from the company’s previous close. HC Wainwright also issued estimates for Sangamo Therapeutics’ FY2028 earnings at $0.64 EPS.

A number of other equities analysts have also recently weighed in on the stock. StockNews.com started coverage on shares of Sangamo Therapeutics in a research report on Sunday, July 28th. They issued a “sell” rating for the company. Barclays increased their price target on Sangamo Therapeutics from $3.00 to $9.00 and gave the company an “overweight” rating in a report on Thursday.

Sangamo Therapeutics Trading Down 4.7 %

NASDAQ SGMO opened at $2.05 on Thursday. The company’s fifty day simple moving average is $1.33 and its 200-day simple moving average is $0.86. The stock has a market cap of $427.67 million, a P/E ratio of -2.73 and a beta of 1.10. Sangamo Therapeutics has a 52 week low of $0.30 and a 52 week high of $3.18.

Institutional Investors Weigh In On Sangamo Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of SGMO. State Board of Administration of Florida Retirement System lifted its position in shares of Sangamo Therapeutics by 61.1% during the first quarter. State Board of Administration of Florida Retirement System now owns 62,345 shares of the biopharmaceutical company’s stock worth $42,000 after purchasing an additional 23,650 shares during the last quarter. Cubist Systematic Strategies LLC bought a new position in Sangamo Therapeutics during the 2nd quarter worth approximately $67,000. Meritage Portfolio Management grew its position in shares of Sangamo Therapeutics by 8.6% in the 3rd quarter. Meritage Portfolio Management now owns 85,000 shares of the biopharmaceutical company’s stock worth $74,000 after acquiring an additional 6,740 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Sangamo Therapeutics in the 2nd quarter valued at approximately $89,000. Finally, XTX Topco Ltd raised its position in shares of Sangamo Therapeutics by 167.8% during the 3rd quarter. XTX Topco Ltd now owns 103,716 shares of the biopharmaceutical company’s stock valued at $90,000 after acquiring an additional 64,981 shares in the last quarter. Institutional investors own 56.93% of the company’s stock.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.